Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Riccardo Lencioni
Author Correction: Combining locoregional treatments and immunotherapies in patients with unresectable hepatocellular carcinoma
Correction to: Nature Reviews Clinical Oncology https://doi.org/10.1038/s41571-026-01210-6, published online 28 October 2026 In the version of the article initially published, Dan Feng was listed with one affiliation but should have had two (Division of Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA and Mount Sinai Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA).
Combining locoregional treatments and immunotherapies in patients with unresectable hepatocellular carcinoma
Abstract The systemic treatment landscape of unresectable hepatocellular carcinoma has been transformed by immune-checkpoint inhibitor (ICI)-based regimens. These advances have led to efforts to combine ICIs with locoregional therapies (LRTs), particularly transarterial chemoembolization, transarterial radioembolization and external beam radiotherapy, in an attempt to improve tumour control and extend the benefits of ICIs to patients with intermediate-stage disease.
“Change of Paradigm Across the Entire Spectrum” of Liver Cancer on the Horizon?
Data from the EMERALD-1 trial have “opened a new horizon” in hepatocellular carcinoma (HCC), says lead author Riccardo Lencioni, MD. The study found that adding durvalumab and bevacizumab to transarterial chemoembolization prolongs progression-free survival (PFS) for patients with unresectable HCC, a population with a large unmet need.
O3-13-4Global GIDEON data: Subgroup analysis of sorafenib dosing pattern in patients with unresectable hepatocellular carcinoma
O3-13-4Global GIDEON data: Subgroup analysis of sorafenib dosing pattern in patients with unresectable hepatocellular carcinoma Masatoshi Kudo1, Sheng-Long Ye2, Keiko Nakajima3 and Riccardo Lencioni4 1Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Higashiosaka City, Osaka, Japan 2Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China 3Global Medical Affairs, Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA 4University of Miami...
RFA plus lyso-thermosensitive liposomal doxorubicin: in search of the optimal approach to cure intermediate-size hepatocellular carcinoma
RFA plus lyso-thermosensitive liposomal doxorubicin: in search of the optimal approach to cure intermediate-size hepatocellular carcinoma When heated during a radiofrequency ablation (RFA) procedure to ≥40°C, lyso-thermosensitive liposomal doxorubicin (LTLD) produces high drug concentration in the surrounding margins of the ablation zone.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Riccardo
Contact Riccardo, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack